IVIXF (Invion) Payments of Debt: $-0.76 Mil (TTM As of Dec. 2025)


IVIXF Invion Ltd IVIXF
16 GF Score
Price $0.04
GF Value $0.17
! 2 Warning Signs
View Full Analysis

What is Invion Payments of Debt?

Invion IVIXF -83.23% 16 Payments of Debt is $-0.76 Mil as of Dec. 2025. GuruFocus rates IVIXF with a GF Score™ of 16/100 and a GF Value™ of $0.17. The stock has 2 warning signs investors should review.

Invion's Payments of Debt for the six months ended in Dec. 2025 was $-0.76 Mil.

Invion's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.76 Mil.

Invion Payments of Debt Related Terms

Invion Payments of Debt Historical Data

* Premium members only.

The historical data trend for Invion's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invion Payments of Debt Chart

Invion Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.48

Invion Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.76
IVIXF
16GF Score
Invion Ltd IVIXF
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invion Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $-0.76 Mil mean?
Invion (IVIXF) has a Payments of Debt of $-0.76 Mil as of Dec. 2025. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Invion and its competitors.
Is Invion's Payments of Debt too high?
Invion's current Payments of Debt is $-0.76 Mil. Overall, Invion has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Invion's Payments of Debt compare to ZTS and UTHR?
Invion's Payments of Debt of $-0.76 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Drug Manufacturers company?
A good Payments of Debt depends on the Drug Manufacturers industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Invion and its competitors. Invion's current Payments of Debt is $-0.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invion stock overvalued right now?
Invion (IVIXF) has a current Payments of Debt of $-0.76 Mil. The stock's GF Value™ is $0.17, compared to a current price of $0.04 — trading 78.3% below its estimated fair value. The current Payments of Debt is $-0.76 Mil. Invion's overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Invion (IVIXF), the current Payments of Debt is $-0.76 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Invion (IVIXF) Overvalued in 2026?

Based on GuruFocus' analysis, Invion stock appears to be undervalued. The current stock price of $0.04 is trading 78.3% below its estimated GF Value™ of $0.17.

Key valuation signals for IVIXF:

  • Payments of Debt: $-0.76 Mil
  • GF Value™: $0.17 vs. price of $0.04 (78.3% below fair value)
  • GF Score™: 16/100 with 2 warning signs

No single metric tells the full story. See the IVIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Invion Business Description

Other Exchanges 7C8:GermanyIVX:Australia
Address 692 High Street, East Kew, VIC, AUS, 3102
Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments called Photosoft, for the treatment of a range of cancers, and infectious diseases. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer. Invion has developed a portfolio of patent protected compounds. Its drug candidate is INV043, a novel photosensitiser which has the potential to work as a therapy and a diagnostic tool.
16GF Score

Get the complete analysis for IVIXF

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.04
Price
$0.17
GF Value